Although these studies clearly report the benefit of targeted therapy in pHGG with BRAF mutation in a tumor type mostly resistant to conventional approaches, the place of this therapy in an upfront setting is still to be proven and is yet to be approved by regulatory agencies for this indication. The gene discussed is BRAF; the disease is neoplasm.